Core Viewpoint - Livzon Pharmaceutical Group Inc. has successfully entered its product, Lakanqita Monoclonal Antibody Injection, into the priority review list by the National Medical Products Administration of China, indicating a significant step towards obtaining market approval for treating moderate to severe plaque psoriasis in adults [1]. Group 1: Product Development - The product, Lakanqita Monoclonal Antibody Injection, is developed in collaboration with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. [1] - The application for the product was submitted on December 18, 2025, and it was publicly announced on December 26, 2025 [1]. Group 2: Regulatory Approval - The product has been included in the priority review list, which allows for expedited approval processes under specific regulatory guidelines [1]. - The inclusion in the priority review list is based on compliance with the Drug Registration Management Measures and other relevant announcements by the National Medical Products Administration [1].
丽珠医药(01513.HK)：莱康奇塔单抗注射液被纳入优先审评审批程序